358 540

Cited 21 times in

Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy

DC Field Value Language
dc.contributor.author이필휴-
dc.date.accessioned2015-05-19T17:24:11Z-
dc.date.available2015-05-19T17:24:11Z-
dc.date.issued2008-
dc.identifier.issn0161-5505-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/108080-
dc.description.abstractWe investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy in patients with Parkinson disease dementia (PDD) to determine whether cognitive improvements would be reflected in changes of cerebral metabolic patterns, thus offering insight into the neural substrate of cognitive dysfunction in patients with PDD. METHODS: We performed a serial PET study before (baseline) and after ChEI therapy on 10 patients with PDD, using statistical parametric mapping. Additionally, covariance analysis was performed to extract regions in which increased change in regional cerebral metabolism correlated significantly with increased Mini-Mental State Examination scores. RESULTS: The statistical parametric mapping analysis indicated that significantly increased cerebral metabolism after ChEI therapy, compared with at baseline, was most evident in the left angular gyrus extending to the supramarginal area and left superior and middle frontal gyri. Additionally, cerebral metabolism was significantly increased in the right superior frontal and left middle orbitofrontal gyri. In contrast, the right fusiform gyrus showed significantly decreased metabolism after ChEI, compared with at baseline. In the correlation analysis, improvements in Mini-Mental State Examination scores after ChEI treatment were significantly associated with increased cerebral metabolism in the left supramarginal, orbitofrontal, and cingulate areas. CONCLUSION: Our data suggest that prefrontal and parietal association areas may be relevant structures for the pharmacologic response to ChEI in patients with PDD.-
dc.description.statementOfResponsibilityopen-
dc.format.extent2006~2011-
dc.relation.isPartOfJOURNAL OF NUCLEAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntiparkinson Agents/administration & dosage-
dc.subject.MESHBrain/drug effects-
dc.subject.MESHBrain/metabolism*-
dc.subject.MESHCholinesterase Inhibitors/administration & dosage*-
dc.subject.MESHDementia/complications-
dc.subject.MESHDementia/diagnostic imaging-
dc.subject.MESHDementia/drug therapy*-
dc.subject.MESHDementia/metabolism*-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18/pharmacokinetics*-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHParkinson Disease/complications-
dc.subject.MESHParkinson Disease/diagnostic imaging-
dc.subject.MESHParkinson Disease/drug therapy*-
dc.subject.MESHParkinson Disease/metabolism*-
dc.subject.MESHRadionuclide Imaging-
dc.subject.MESHRadiopharmaceuticals/pharmacokinetics-
dc.subject.MESHTissue Distribution/drug effects-
dc.subject.MESHTreatment Outcome-
dc.titleChanges in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학)-
dc.contributor.googleauthorPhil Hyu Lee-
dc.contributor.googleauthorSeok Woo Yong-
dc.contributor.googleauthorYoung-Sil An-
dc.identifier.doi10.2967/jnumed.108.054668-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03270-
dc.relation.journalcodeJ01644-
dc.identifier.eissn1535-5667-
dc.identifier.pmid18997034-
dc.subject.keywordAged-
dc.subject.keywordAged, 80 and over-
dc.subject.keywordAntiparkinson Agents/administration & dosage-
dc.subject.keywordBrain/drug effects-
dc.subject.keywordBrain/metabolism*-
dc.subject.keywordCholinesterase Inhibitors/administration & dosage*-
dc.subject.keywordDementia/complications-
dc.subject.keywordDementia/diagnostic imaging-
dc.subject.keywordDementia/drug therapy*-
dc.subject.keywordDementia/metabolism*-
dc.subject.keywordFemale-
dc.subject.keywordFluorodeoxyglucose F18/pharmacokinetics*-
dc.subject.keywordHumans-
dc.subject.keywordMale-
dc.subject.keywordParkinson Disease/complications-
dc.subject.keywordParkinson Disease/diagnostic imaging-
dc.subject.keywordParkinson Disease/drug therapy*-
dc.subject.keywordParkinson Disease/metabolism*-
dc.subject.keywordRadionuclide Imaging-
dc.subject.keywordRadiopharmaceuticals/pharmacokinetics-
dc.subject.keywordTissue Distribution/drug effects-
dc.subject.keywordTreatment Outcome-
dc.contributor.alternativeNameLee, Phil Hyu-
dc.contributor.affiliatedAuthorLee, Phil Hyu-
dc.rights.accessRightsfree-
dc.citation.volume49-
dc.citation.number12-
dc.citation.startPage2006-
dc.citation.endPage2011-
dc.identifier.bibliographicCitationJOURNAL OF NUCLEAR MEDICINE, Vol.49(12) : 2006-2011, 2008-
dc.identifier.rimsid35171-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.